ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,743Medicare Part D Prescriptions Filled, Including Refills

Rank: 80 out of 252

$587K Total Retail Price of All Prescriptions

Rank: 77 out of 252

623 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

10% of this provider’s 623 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 9,863 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
LEVOTHYROXINE SODIUM 507 477 1 1
PRAVASTATIN SODIUM 432 392 2 12
LISINOPRIL 409 392 3 3
SIMVASTATIN 376 369 4 2
OMEPRAZOLE 374 353 5 6
HYDROCODONE-ACETAMINOPHEN 326 204 S3 6 5
AMLODIPINE BESYLATE 321 306 7 4
HYDROCHLOROTHIAZIDE 287 279 8 13
METFORMIN HCL 260 242 9 9
METOPROLOL TARTRATE 223 200 10 10
FUROSEMIDE 217 199 11 7
WARFARIN SODIUM 199 199 12 14
ZOLPIDEM TARTRATE 196 183 13 21
ATORVASTATIN CALCIUM 189 176 14 16
POTASSIUM CHLORIDE 187 175 15 8
CITALOPRAM HBR 181 169 16 15
METOPROLOL SUCCINATE 176 162 17 19
ATENOLOL 165 158 18 18
ALENDRONATE SODIUM 159 146 19 32
LOSARTAN POTASSIUM 149 127 20 24
TRAMADOL HCL 122 122 21 17
DONEPEZIL HCL 104 104 22 28
GABAPENTIN 99 98 23 11
ZETIA 99 99 23 97
AMITRIPTYLINE HCL 97 92 R 25 46
LISINOPRIL-HYDROCHLOROTHIAZIDE 93 88 26 25
CARVEDILOL 93 93 26 22
NEXIUM 92 79 28 23
TAMSULOSIN HCL 92 79 28 26
SERTRALINE HCL 86 74 30 27
LOSARTAN-HYDROCHLOROTHIAZIDE 79 64 31 49
CRESTOR 79 62 31 34
TRAZODONE HCL 74 69 33 31
TRIAMTERENE-HCTZ 73 72 34 33
SYNTHROID 70 70 35 47
CLONIDINE HCL 69 68 36 35
TERAZOSIN HCL 67 67 37 94
DOXAZOSIN MESYLATE 66 66 38 73
CLOPIDOGREL 64 59 39 29
MELOXICAM 64 58 39 20
ALLOPURINOL 64 64 39 30
LOVASTATIN 62 62 42 39
FLUTICASONE PROPIONATE 61 61 43 36
BENICAR 61 61 43 143
PAROXETINE HCL 58 58 45 75
KLOR-CON M20 56 56 46 69
FLUOXETINE HCL 54 53 47 57
GLIPIZIDE 53 41 48 52
DIGOXIN 51 51 49 44
GEMFIBROZIL 51 51 49 98
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 25, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.